DGX
Quest Diagnostics Inc
$
167.930
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
169.615
Open
168.720
VWAP
--
Vol
810.66K
Mkt Cap
18.78B
Low
167.0272
Amount
--
EV/EBITDA(TTM)
11.58
Total Shares
111.09M
EV
24.25B
EV/OCF(TTM)
14.45
P/S(TTM)
1.82
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
2.74B
+3.47%
2.373
+7.37%
2.74B
+4.63%
2.413
+8.21%
2.74B
+9.97%
2.512
+9.2%
Estimates Revision
The market is revising Upward the revenue expectations for Quest Diagnostics Incorporated (DGX) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by -5.77%.
Revenue Estimates for FY2025
Revise Upward
+0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.02%
In Past 3 Month
Stock Price
Go Down
-5.77%
In Past 3 Month
13 Analyst Rating
12.11% Upside
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 188.27 USD with a low forecast of 175.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
7 Hold
0 Sell
Moderate Buy
12.11% Upside
Current: 167.930
Low
175.00
Averages
188.27
High
200.00
12.11% Upside
Current: 167.930
Low
175.00
Averages
188.27
High
200.00
Piper Sandler
David Westenberg
Neutral
downgrade
$200 -> $190
2025-07-28
New
Reason
Piper Sandler
David Westenberg
Price Target
$200 -> $190
2025-07-28
New
downgrade
Neutral
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Quest Diagnostics to $190 from $200 following quarterly results. The firm keeps a Neutral rating on the shares.
Deutsche Bank
Pito Chickering
Hold
maintain
$160 -> $178
2025-07-23
Reason
Deutsche Bank
Pito Chickering
Price Target
$160 -> $178
2025-07-23
maintain
Hold
Reason
Deutsche Bank analyst Pito Chickering raised the firm's price target on Quest Diagnostics to $178 from $160 and keeps a Hold rating on the shares.
Truist
Hold
maintain
$190 -> $192
2025-07-23
Reason
Truist
Price Target
$190 -> $192
2025-07-23
maintain
Hold
Reason
Truist raised the firm's price target on Quest Diagnostics to $192 from $190 and keeps a Hold rating on the shares. Quest's Q2 results came in ahead of consensus expectations on the top- and bottom-lines, with FY25 guidance moved up as core demand trends remain strong, organic volumes were solid with brisk organic revenue and organic growth expectations were raised, the analyst tells investors in a research note.
UBS
Neutral
maintain
$175 -> $180
2025-07-23
Reason
UBS
Price Target
$175 -> $180
2025-07-23
maintain
Neutral
Reason
UBS raised the firm's price target on Quest Diagnostics to $180 from $175 and keeps a Neutral rating on the shares. UBS says Quest's Q2 results were "good enough."
Morgan Stanley
Erin Wright
Overweight
maintain
$182 -> $191
2025-07-23
Reason
Morgan Stanley
Erin Wright
Price Target
$182 -> $191
2025-07-23
maintain
Overweight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Quest Diagnostics to $191 from $182 and keeps an Overweight rating on the shares following a "clean beat and raise" report. Quest raised its 2025 EPS guidance to $9.63-$9.83 and projects the favorable environment should now support 9.4%-10.6% revenue growth in 2025 as strong utilization persists, the analyst noted.
Evercore ISI
Elizabeth Anderson
In Line
maintain
$180 -> $185
2025-07-23
Reason
Evercore ISI
Elizabeth Anderson
Price Target
$180 -> $185
2025-07-23
maintain
In Line
Reason
Evercore ISI analyst Elizabeth Anderson raised the firm's price target on Quest Diagnostics to $185 from $180 and keeps an In Line rating on the shares following what the firm calls "a solid 2Q performance" as well as an uplift in 2025 guidance. The firm, which cites improved business trends, excluding policy impacts, for its target increase, sees Quest having "manageable risks and a path forward for growth beyond 2026."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Quest Diagnostics Inc (DGX.N) is 16.67, compared to its 5-year average forward P/E of 14.91. For a more detailed relative valuation and DCF analysis to assess Quest Diagnostics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
14.91
Current PE
16.67
Overvalued PE
17.37
Undervalued PE
12.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
10.46
Current EV/EBITDA
11.54
Overvalued EV/EBITDA
11.71
Undervalued EV/EBITDA
9.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.71
Current PS
1.70
Overvalued PS
1.85
Undervalued PS
1.56
Financials
Annual
Quarterly
FY2025Q2
YoY :
+15.19%
2.76B
Total Revenue
FY2025Q2
YoY :
+26.29%
466.00M
Operating Profit
FY2025Q2
YoY :
+19.58%
287.00M
Net Income after Tax
FY2025Q2
YoY :
+22.55%
2.50
EPS - Diluted
FY2025Q2
YoY :
+62.69%
436.00M
Free Cash Flow
FY2025Q2
YoY :
+1.14%
32.74
Gross Profit Margin - %
FY2025Q2
YoY :
+24.25%
11.63
FCF Margin - %
FY2025Q2
YoY :
+7.09%
10.72
Net Margin - %
FY2025Q2
YoY :
+6.44%
9.58
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
306.8K
USD
2
3-6
Months
9.0M
USD
6
6-9
Months
14.9M
USD
11
0-12
Months
5.6M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1536.08% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
51.4K
Volume
2
6-9
Months
84.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
346.0K
Volume
Months
6-9
4
21.1K
Volume
Months
0-12
1
1.4K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
8.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
306.8K
USD
2
3-6
Months
9.0M
USD
6
6-9
Months
14.9M
USD
11
0-12
Months
5.6M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DGX News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
06:53:15
Quest Diagnostics raises FY25 adjusted EPS view to $9.63-$9.83 from $9.55-$9.80
2025-07-22
06:50:43
Quest Diagnostics reports Q2 adjusted EPS $2.62, consensus $2.58
2025-07-21 (ET)
2025-07-21
20:25:00
Notable companies reporting before tomorrow's open
Sign Up For More Events
Sign Up For More Events
News
5.0
07-29NewsfilterAthena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
8.0
07-24BenzingaOptions Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity
4.0
07-23BenzingaTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $192
Sign Up For More News
People Also Watch
YPF
YPF SA
34.810
USD
+4.75%
GPC
Genuine Parts Co
133.460
USD
+0.29%
RBA
RB Global Inc
108.500
USD
+0.02%
GFL
GFL Environmental Inc
48.750
USD
+1.29%
TPR
Tapestry Inc
107.400
USD
-2.74%
MANH
Manhattan Associates Inc
225.410
USD
+1.78%
FLEX
Flex Ltd
51.800
USD
+2.59%
MAS
Masco Corp
66.650
USD
-1.26%
OMC
Omnicom Group Inc
74.320
USD
-0.42%
ALGN
Align Technology Inc
205.810
USD
-0.67%
FAQ
What is Quest Diagnostics Inc (DGX) stock price today?
The current price of DGX is 167.93 USD — it has increased 0.05 % in the last trading day.
What is Quest Diagnostics Inc (DGX)'s business?
What is the price predicton of DGX Stock?
What is Quest Diagnostics Inc (DGX)'s revenue for the last quarter?
What is Quest Diagnostics Inc (DGX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Quest Diagnostics Inc (DGX)'s fundamentals?
How many employees does Quest Diagnostics Inc (DGX). have?